Femasys

Femasys, Inc. operates as a medical device company that focuses on women's healthcare. Its products include FemVue Saline-Air Device, which creates and delivers an alternating pattern of saline and air as a continuous stream, and enables physicians to assess their patients fallopian tubes, and FemChec Pressure Management Device, which limits the maximum applied pressure while performing hysterosalpingogram. The firm offers FemCerv, an endocervical curettage device to collect a non-contaminated tissue sample for cervical cancer screening. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.

ATLANTA, July 11, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company has been invited to present at the Women's Health Panel Discussion, presented by Maxim Group LLC and hosted by M-Vest, on Wednesday, July 13th, 2022 at 11:00 a.m. ET.

Femasys to Participate in the Women's Health Panel Discussion Presented by Maxim Group LLC and hosted by M-Vest on Wednesday, July 13th at 11 a.m. ET

Agile Therapeutics

Evofem Biosciences Inc

Here's what you need to know about buying penny stocks on June 28th The post What to Know About Buying Penny Stocks on June 28th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on June 28th

- Furthers advancement of much-needed minimally invasive technologies for underserved areas of women's health with pending commercialization of products, FemCerv ® and FemCath ™ expected by year-end

Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2022

ATLANTA, March 25, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company will participate in a panel at the 2022 Virtual Growth Conference, hosted by Maxim Group LLC and M-Vest, being held March 28th – 30th from 9:00 am – 5:30 pm ET.

Femasys Inc. to Participate in the M-Vest 2022 Virtual Growth Conference

-- Company builds out management team and continues to implement its clinical programs to advance much-needed technologies for women's health -- ATLANTA, March 24, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced financial results for the year ended December 31, 2021.

Femasys Inc. Announces Financial Results for the Year Ended December 31, 2021

ATLANTA, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company is participating in the LifeSci Partners 11th Annual Corporate Access Event, which will be held virtually from January 5-7, 2022, and the H.C. Wainwright BioConnect Conference, which will be held virtually from January 10-13, 2022.

Femasys Inc. to Participate in Upcoming January Investor Conferences

ATLANTA, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that Kathy Lee-Sepsick, chairman, president and chief executive officer, will participate in a presentation at The MedTech Conference. Ms. Lee-Sepsick will speak on a panel in a session, entitled, “Early-Stage Medtech and Going Public.” The MedTech Conference, an annual event powered by AdvaMed, convenes the world's leaders in medical technology and will be held on a hybrid basis from September 21st-30th this year.

Femasys Inc. to Present at The MedTech Conference

ATLANTA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a biomedical company developing a suite of product candidates to transform women's healthcare with minimally invasive, non-surgical, in-office technologies, announced that the Company has been added to the Russell Microcap® Index today when the U.S. market opened. The Russell Microcap Index is widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

Femasys Inc. To Join the Russell Microcap® Index

-- Industry veteran with over than two decades of experience in medical affairs to lead clinical and medical affairs at Femasys -- ATLANTA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company developing a suite of product candidates to transform women's healthcare with minimally invasive, non-surgical, in-office technologies, today announced the appointment of Edward G. Evantash, M.D., as chief medical officer. Dr. Evantash brings over two decades of industry experience in medical and clinical affairs to Femasys, having previously served as chief medical officer of Alydia Health and vice president of medical affairs at Hologic, Inc., both medical technology companies focused on women's healthcare. He will be responsible for providing leadership and direction for Femasys' pipeline of clinical development programs.

Femasys Inc. Announces the Appointment of Edward Evantash, M.D. as Chief Medical Officer

The stock price of Femasys Inc (NASDAQ: FEMY) increased by over 35% during intraday trading. This is why it happened.

FEMY Stock Increases Over 35% Intraday: Why It Happened

First in Class Insemination Treatment for Infertility

Femasys Inc. Announces First Patient Treated in Pivotal Trial for FemaSeed

Femasys has the potential to transform both birth control and infertility, both of which are multibillion-dollar markets. The company has received a $50mil investment from Medtronic and more recently, existing investors bought into the IPO.

Femasys: Revolutionizing Female Reproduction

NEW YORK, June 21, 2021 /PRNewswire/ -- Chardan, a global investment bank, today announced that it acted as lead left bookrunner in the successful closing of the $34.45 million IPO of Femasys, Inc. (NASDAQ: FEMY) a biomedical company focused on transforming women's healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. "We are delighted to work with the outstanding team at Femasys in support of their commitment to women's healthcare," said Matthew Mrozinski, a partner in the investment banking group at Chardan.

Chardan Acts as Lead Left Bookrunner in Femasys' $34.45 Million IPO

Atai Life Sciences BV

Ambrx Biopharma Inc

Cyteir Therapeutics

Codex DNA

Century Therapeutics

Going public on Friday: atai Life Sciences, Ambrx Biopharma, Century Therapeutics, Codex DNA, Cyteir Therapeutics, and Femasys.

Peter Thiel's Atai Life Sciences and 5 Other Companies List Shares

News for Femasys Stock (FEMY)